Author | Year | Treatment | Patients | FEV1 % pred | Exac.·Patient·yr−1 | Δ% | p-value |
Calverley [8] | 2003 | Formoterol 9 µg b.i.d. | 255 | 36 | 0.91 | −20 | ns |
Placebo | 256 | 36 | 1.14# | ||||
Szafranski [9] | 2003 | Formoterol 4.5 µg b.i.d. | 201 | 36 | 1.84 | ns | |
Placebo | 205 | 36 | 1.87 | ||||
Calverley [10] | 2003 | Salmeterol 50 µg b.i.d. | 372 | 44 | 0.54 | −29 | 0.0003 |
Placebo | 361 | 44 | 0.76 | ||||
Brusasco [11] | 2003 | Salmeterol 50 µg b.i.d. | 405 | 38 | 1.23 | −17 | ns |
Placebo | 400 | 39 | 1.49 |
FEV1: forced expiratory volume in one second; % pred: % predicted; Exac: exacerbations; ns: nonsignificant. #: exacerbations requiring oral steroid treatment.